X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the agreement, ARS Pharmaceuticals Reacquires commercial rights to neffy (ARS-1) in the European region. Neffy is an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions leading to anaphylaxis.
Lead Product(s): Epinephrine
Therapeutic Area: Immunology Product Name: Neffy
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: ARS Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 22, 2023
Details:
Isturisa (osilodrostat phosphate) is an oral inhibitor of 11β-hydroxylase (CYP11B1), which catalyses the final step of cortisol synthesis in the adrenal glands. Isturisa® is available as 1 mg, 5 mg and 10 mg film-coated tablets.
Lead Product(s): Osilodrostat
Therapeutic Area: Endocrinology Product Name: Isturisa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
ISTURISA (osilodrostat), is a cortisol synthesis inhibitor indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.
Lead Product(s): Osilodrostat
Therapeutic Area: Endocrinology Product Name: Isturisa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
Recordati will expand its pipeline by acquiring EUSA Pharma pipeline and enhances the breadth of indications which include Qarziba®, an anti-GD2 monoclonal antibody, Sylvant®, an anti-IL-6 monoclonal antibody, Fotivda®, an oral highly selective small molecule.
Lead Product(s): Dinutuximab
Therapeutic Area: Oncology Product Name: Qarziba
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Eusa Pharma
Deal Size: $847.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 03, 2021
Details:
Eligard® is a marketed medicinal product for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localized and locally advanced hormone dependent prostate cancer in combination with radiotherapy.
Lead Product(s): Leuprolide Acetate
Therapeutic Area: Oncology Product Name: Eligard
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Tolmar
Deal Size: $168.6 million Upfront Cash: $42.1 million
Deal Type: Licensing Agreement January 29, 2021
Details:
Data from the Phase III LINC-3 study, published in Lancet Diabetes & Endocrinology, demonstrate that Isturisa® (osilodrostat) rapidly decreases mean urinary free cortisol (mUFC) in patients with Cushing’s disease.
Lead Product(s): Osilodrostat
Therapeutic Area: Endocrinology Product Name: Isturisa
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2020
Details:
In the Phase 3 LINC?3 study, a significantly higher proportion of patients treated with Isturisa® (osilodrostat) maintained normal mean urinary free cortisol (mUFC) at the end of the 8?week.
Lead Product(s): Osilodrostat
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
